Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $2.8 million.

  • Addex Therapeutics' Cash & Equivalents rose 1517.44% to $2.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.8 million, marking a year-over-year increase of 1517.44%. This contributed to the annual value of $3.8 million for FY2024, which is 11.74% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Cash & Equivalents is $2.8 million, which was down 11.56% from $3.1 million recorded in Q1 2025.
  • Over the past 5 years, Addex Therapeutics' Cash & Equivalents peaked at $7,973.3 billion during Q2 2023, and registered a low of -$2,323.3 billion during Q3 2023.
  • Over the past 3 years, Addex Therapeutics' median Cash & Equivalents value was $3.5 million (recorded in 2025), while the average stood at $565.0 billion.
  • Over the last 5 years, Addex Therapeutics' Cash & Equivalents had its largest YoY gain of 87,136,269.06% in 2023, and its largest YoY loss of 22,235,074.73% in 2023.
  • Over the past 4 years, Addex Therapeutics' Cash & Equivalents (Quarterly) stood at $7.2 million in 2022, then slumped by 39.66% to $4.4 million in 2023, then dropped by 12.46% to $3.8 million in 2024, then spiked by 1,517.44% to $2.8 million in 2025.
  • Its Cash & Equivalents stands at $2.8 million for Q2 2025, versus $3.1 million for Q1 2025 and $3.8 million for Q4 2024.